Incidence and Risk Factors for Urolithiasis in Patients with Crohn's Disease

Kim, Min Jung; Woo, Sook‐Young; Kim, Eun Ran; Hong, Sung Noh; Chang, Dong Kyung; Rhee, Poong–Lyul; Kim, Jae J; Rhee, Jong Chul; Kim, Young‐Ho

doi:10.1159/000375536

Cited by 5 publications

(6 citation statements)

References 17 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…7 Most studies linking IBD with risk of urolithiasis are older or based on small or selected patient populations. [2][3][4][5][6]8 Hence, the magnitude of risk of urolithiasis in IBD remains uncertain.…”

Section: Introductionmentioning

confidence: 99%

Risk of Urolithiasis in Patients With Inflammatory Bowel Disease: A Nationwide Danish Cohort Study 1977–2018

Dimke

Winther-Jensen

Allin

et al. 2021

Clinical Gastroenterology and Hepatology

View full text Add to dashboard Cite

Section: Introductionmentioning

confidence: 99%

Risk of Urolithiasis in Patients With Inflammatory Bowel Disease: A Nationwide Danish Cohort Study 1977–2018

Dimke

Winther-Jensen

Allin

et al. 2021

Clinical Gastroenterology and Hepatology

View full text Add to dashboard Cite

“…Finally, 32 articles (n = 13,339,065 patients) were included in the qualitative (systematic review) and quantitative synthesis (meta-analysis). [12–16,21–47] Figure 1 shows the Preferred Reporting Items for Systematic Reviews and Meta-Analyses flow diagram of included studies.…”

Section: Resultsmentioning

confidence: 99%

“…On the other hand, we found a nonsignificant association between developing urolithiasis and age (OR = 1.056, 95% CI: 0.947–1.164), type of IBD (OR = 1.056, 95% CI: 0.467–1.645), and 5-aminosalicylic acid concurrent medication (OR = 0.996, 95% CI: 0.976–1.016). Individual studies [ 29 , 33 , 35 , 36 , 38 , 39 ] showed that there was a significant association between developing urolithiasis and the disease duration of IBD (OR = 1.03, 95% CI: 1.01–1.05), the presence of fistula, fissure, or abscess (OR = 2.01, 95% CI: 1.32–3.07), existence of stenosis (OR = 1.82, 95% CI: 1.18–2.8), NSAID intake (OR = 2.334, 95% CI: 1.415–3.851), activity index (OR = 1.032, 95% CI: 1.018–1.045), active UC (OR = 4.2, 95% CI: 1.1–15), white race (OR = 1.49, 95% CI: 1.087–2.048), number of bowel resections (OR = 1.415, 95% CI: 1.17–1.71), and CD treatment period (OR = 1.076, 95% CI: 1.04–1.113), Table 3 .…”

Section: Resultsmentioning

confidence: 99%

“…Regarding CD, the prevalence of urolithiasis was 7.1%, 95% CI (3.6%-13.6%), nephrolithiasis 4.6%, 95% CI (3.6%-5.8%), and both 11.9%, 95% CI (8.4%-16.6%). Based on [29,33,35,36,38,39] showed that there was a significant association between developing urolithiasis and the disease duration of IBD (OR = 1.03, 95% CI: 3.…”

Section: Prevalence Of Renal Stones In Ibd Patientsmentioning

confidence: 99%

See 1 more Smart Citation

Urolithiasis in patients with inflammatory bowel disease: A systematic review and meta-analysis of 13,339,065 individuals

Abdulrhman,

Alsweed,

Alotaibi

et al. 2023

Medicine

View full text Add to dashboard Cite

Background: This study aimed to summarize the current literature regarding the prevalence of renal stones in patients with inflammatory bowel disease (IBD). Moreover, we aimed to evaluate the risk factors of urolithiasis in patients with IBD and the difference between patients with IBD and healthy controls in terms of urinary profile.Methods: On February 23, 2022, a computerized search was conducted on PubMed, OVID via MEDLINE, Web of Science, and Scopus using relevant keywords. Three independent reviewers performed 2-stage screening and data extraction. The National Institutes of Health tools were employed for quality assessment. Review Manager 5.4 software was used to calculate the mean difference (MD) between IBD patients and non-IBD in terms of urine profile using the Inverse-variance model and to estimate the odds ratio of reported risk factors for renal stones with the Generic Inverse-Variance model.Results: Thirty-two articles (n = 13,339,065 patients) were included. The overall prevalence of renal stones in patients with IBD was 6.3%, 95% Confidence interval (4.8%-8.3%). The prevalence of urolithiasis was more common in Chron's disease vs Ulcerative colitis (7.9% vs 5.6%) and in old studies than in more recent studies (2010-2022) (7.3% vs 5.2%), respectively. Compared to non-IBD patients, patients with IBD were associated with significantly lower urine volume (MD = −518.84 mL/day, P < .00001), calcium 24-hour urine (MD = −28.46 mg/day, P < .0001), citrate 24-hour urine (MD = −144.35 mg/day, P < .00001), sodium 24-hour urine (MD = −23.72 mg/day, P = .04), and magnesium 24-hour urine (MD = −33.25 mg/day, P < .00001). Conclusion:The overall prevalence of renal stones in patients with IBD was comparable to the general population. Patients with Chron's disease were associated with a higher prevalence of urolithiasis compared to Ulcerative colitis. Drugs that induce renal calculi should be stopped in high-risk patients.

show abstract

“…Bacterial species which can exchange Ox and convert this to formate have the potential to reduce the amount of Ox present in the GIT thereby reducing circulating CaOx. Increasing the abundance of species with these capabilities could be beneficial in patients suffering from CD as it has been reported that these patients have a 10-100 fold higher chance of developing kidney stones compared to healthy controls and patients with UC (Kim et al, 2015, Gaspar et al, 2016. Further investigations as to whether Flavonifractor spp.…”

Section: Discussionmentioning

confidence: 99%

Genetic and biochemical analysis of host-microbe interactions affecting gut homeostasis: functional and genomic analysis of polyphenol catabolism by bacteria from Clostridium cluster IV

Pottenger¹

View full text Add to dashboard Cite

Metagenomics offers opportunities to advance our understanding of the complexities of the microbia l communities that inhabit the human gastrointestinal tract (GIT). Whilst this research field has great potential, there are limitations and caveats that affect its impact, and the translation of the "microbiome into medicine". In particular, the number of representative microbes that still remain uncultured is substantial and constrains our capacity to define the functional roles such microbes play in health and disease. New techniques to gain representative isolates of these microbes are required, and it would also be advantageous if these microbes are amenable to genetic manipulatio n.Techniques in bacterial genetics applied to a broader diversity of human GIT bacteria would allow us to fully assess the functional aspects of their potential interactions with a host, which would expand understanding of their relation to host health and well-being. With this in mind, the aims of my PhD project were to utilize a new approach developed in our lab referred to as metaparental mating, to expand our collection of genetically tractable bacteria considered relevant to GIT homeostasis, and then assess their immunomodulatory capacity. Based on these results and findings, I then chose to undertake a more detailed and integrated culture-based and genomic analysis of two "new" bacterial isolates assigned to poorly populated and relatively uncharacterised lineages within Clostridium Cluster IV: the genera Flavonifractor and Pseudoflavonifractor.Chapter 1 provides an overview of the current literature with a focus on the roles of the GIT microbiota and its roles in host health and well-being. I provide evidence and rationale for the basis of the research undertaken throughout my PhD studies based on the gaps in our knowledge of the roles specific members of the microbiota play in the GIT of humans Specific focuses are highlighted with regards to the increasing interest in Polyphenols and their beneficial impacts on the microbiota and the host.Chapter 2 describes my use of the metaparental mating technique to recover representative isolates of Firmicutes-affiliated bacteria. I validated the utility of the metaparental mating technique to recover a broad diversity of the bacteria present in human stool assigned to these lineages, and in particular the use of a plasmid that contains the evoglow-C-Bs2 bioluminescence reporter gene, which augmented antibiotic resistance selection and the identification of transconjugant strains. My phylogenetic assessment of the isolates I recovered shows the collection includes bacteria assigned to Enterococcus, Clostridium clusters IV, XIVa and XVIII. I then assessed 22 of my recovered isolates for their ability to inhibit lipopolysaccharide-stimulated NF-κB activation of the lucifer ase reporter gene using the RAW 264.7 mouse macrophage cell line. I was able to show that 7/22 of these iii isolates inhibit NF-κB activation of the reporter gene to a magnitude similar or greater than Faecalibacterium ...

show abstract

Incidence and Risk Factors for Urolithiasis in Patients with Crohn's Disease

Cited by 5 publications

References 17 publications

Risk of Urolithiasis in Patients With Inflammatory Bowel Disease: A Nationwide Danish Cohort Study 1977–2018

Risk of Urolithiasis in Patients With Inflammatory Bowel Disease: A Nationwide Danish Cohort Study 1977–2018

Urolithiasis in patients with inflammatory bowel disease: A systematic review and meta-analysis of 13,339,065 individuals

Genetic and biochemical analysis of host-microbe interactions affecting gut homeostasis: functional and genomic analysis of polyphenol catabolism by bacteria from Clostridium cluster IV

Contact Info

Product

Resources

About